Immuneering Corporation (NASDAQ:IMRX) Stock Has Average Price Target of $15.71

Immuneering Corporation (NASDAQ:IMRX) has been given a consensus recommendation of “Buy” by the seven ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $15.71.

A number of analysts recently commented on IMRX shares. UBS Group set a $14.00 target price on Immuneering in a research report on Thursday, August 6th. Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Immuneering in a research report on Thursday, August 27th. Needham & Company LLC upped their target price on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th.

Immuneering Trading Up 6.4%

Shares of Immuneering stock opened at $3.64 on Friday. The firm’s 50 day moving average is $4.55 and its 200 day moving average is $4.81. The firm has a market capitalization of $235.50 million, a PE ratio of -3.50 and a beta of 0.46. Immuneering has a 1 year low of $3.38 and a 1 year high of $8.48.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). As a group, research analysts anticipate that Immuneering will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Large investors have recently modified their holdings of the business. WINTON GROUP Ltd bought a new position in shares of Immuneering in the second quarter valued at approximately $86,000. Integrated Wealth Concepts LLC bought a new stake in shares of Immuneering during the 2nd quarter valued at about $34,000. Corient Private Wealth LP purchased a new stake in Immuneering in the second quarter valued at approximately $385,000. Focus Financial Network Inc. bought a new stake in shares of Immuneering during the 2nd quarter worth $62,000. Finally, PVG Asset Management Corp bought a new position in Immuneering in the first quarter valued at $773,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancers driven by abnormal signaling through the RAS/MAPK pathway. The company applies computational biology and its Deep Cyclic Inhibition approach to design therapies intended to provide sustained pathway suppression while allowing normal cells periods of recovery.

Immuneering’s lead product candidate, IMM-1-104, is an oral therapy being developed for patients with RAS-mutated solid tumors, including pancreatic cancer.